478 related articles for article (PubMed ID: 30342077)
1. Successful intracranial delivery of trastuzumab by gene-therapy for treatment of HER2-positive breast cancer brain metastases.
Zafir-Lavie I; Sherbo S; Goltsman H; Badinter F; Yeini E; Ofek P; Miari R; Tal O; Liran A; Shatil T; Krispel S; Shapir N; Neil GA; Benhar I; Panet A; Satchi-Fainaro R
J Control Release; 2018 Dec; 291():80-89. PubMed ID: 30342077
[TBL] [Abstract][Full Text] [Related]
2. Intrathecal Viral Vector Delivery of Trastuzumab Prevents or Inhibits Tumor Growth of Human HER2-Positive Xenografts in Mice.
Rothwell WT; Bell P; Richman LK; Limberis MP; Tretiakova AP; Li M; Wilson JM
Cancer Res; 2018 Nov; 78(21):6171-6182. PubMed ID: 30154145
[TBL] [Abstract][Full Text] [Related]
3. Growth inhibition in a brain metastasis model by antibody delivery using focused ultrasound-mediated blood-brain barrier disruption.
Kobus T; Zervantonakis IK; Zhang Y; McDannold NJ
J Control Release; 2016 Sep; 238():281-288. PubMed ID: 27496633
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer.
Liikanen I; Tähtinen S; Guse K; Gutmann T; Savola P; Oksanen M; Kanerva A; Hemminki A
Mol Cancer Ther; 2016 Sep; 15(9):2259-69. PubMed ID: 27458139
[TBL] [Abstract][Full Text] [Related]
5. Sustained secretion of anti-tumor necrosis factor α monoclonal antibody from ex vivo genetically engineered dermal tissue demonstrates therapeutic activity in mouse model of rheumatoid arthritis.
Zafir-Lavie I; Miari R; Sherbo S; Krispel S; Tal O; Liran A; Shatil T; Badinter F; Goltsman H; Shapir N; Benhar I; Neil GA; Panet A
J Gene Med; 2017 Aug; 19(8):. PubMed ID: 28658716
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis.
Lewis Phillips GD; Nishimura MC; Lacap JA; Kharbanda S; Mai E; Tien J; Malesky K; Williams SP; Marik J; Phillips HS
Breast Cancer Res Treat; 2017 Aug; 164(3):581-591. PubMed ID: 28493046
[TBL] [Abstract][Full Text] [Related]
7. Neural stem cells as a novel platform for tumor-specific delivery of therapeutic antibodies.
Frank RT; Edmiston M; Kendall SE; Najbauer J; Cheung CW; Kassa T; Metz MZ; Kim SU; Glackin CA; Wu AM; Yazaki PJ; Aboody KS
PLoS One; 2009 Dec; 4(12):e8314. PubMed ID: 20016813
[TBL] [Abstract][Full Text] [Related]
8. Neural Stem Cells Secreting Anti-HER2 Antibody Improve Survival in a Preclinical Model of HER2 Overexpressing Breast Cancer Brain Metastases.
Kanojia D; Balyasnikova IV; Morshed RA; Frank RT; Yu D; Zhang L; Spencer DA; Kim JW; Han Y; Yu D; Ahmed AU; Aboody KS; Lesniak MS
Stem Cells; 2015 Oct; 33(10):2985-94. PubMed ID: 26260958
[TBL] [Abstract][Full Text] [Related]
9. Adeno-associated virus-mediated trastuzumab delivery to the central nervous system for human epidermal growth factor receptor 2+ brain metastasis.
Werner MS; Aras S; Morgan AR; Roamer J; Param NJ; Olagbegi K; Lamontagne RJ; Greig JA; Wilson JM
Cancer Gene Ther; 2024 May; 31(5):766-777. PubMed ID: 38480976
[TBL] [Abstract][Full Text] [Related]
10. TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.
Mercogliano MF; De Martino M; Venturutti L; Rivas MA; Proietti CJ; Inurrigarro G; Frahm I; Allemand DH; Deza EG; Ares S; Gercovich FG; Guzmán P; Roa JC; Elizalde PV; Schillaci R
Clin Cancer Res; 2017 Feb; 23(3):636-648. PubMed ID: 27698002
[TBL] [Abstract][Full Text] [Related]
11. Phosphodiesterase type 5 inhibitors increase Herceptin transport and treatment efficacy in mouse metastatic brain tumor models.
Hu J; Ljubimova JY; Inoue S; Konda B; Patil R; Ding H; Espinoza A; Wawrowsky KA; Patil C; Ljubimov AV; Black KL
PLoS One; 2010 Apr; 5(4):e10108. PubMed ID: 20419092
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneous distribution of trastuzumab in HER2-positive xenografts and metastases: role of the tumor microenvironment.
Baker JHE; Kyle AH; Reinsberg SA; Moosvi F; Patrick HM; Cran J; Saatchi K; Häfeli U; Minchinton AI
Clin Exp Metastasis; 2018 Oct; 35(7):691-705. PubMed ID: 30196384
[TBL] [Abstract][Full Text] [Related]
13. mRNA Delivery for Therapeutic Anti-HER2 Antibody Expression In Vivo.
Rybakova Y; Kowalski PS; Huang Y; Gonzalez JT; Heartlein MW; DeRosa F; Delcassian D; Anderson DG
Mol Ther; 2019 Aug; 27(8):1415-1423. PubMed ID: 31160223
[TBL] [Abstract][Full Text] [Related]
14. Preclinical and Preliminary Clinical Evaluation of Genetically Transduced Dermal Tissue Implants for the Sustained Secretion of Erythropoietin and Interferon α.
Shapir N; Miari R; Blum S; Schwartz D; Chernin G; Neil GA; Afik D; Panet A
Hum Gene Ther Clin Dev; 2015 Dec; 26(4):216-27. PubMed ID: 26684446
[TBL] [Abstract][Full Text] [Related]
15. Nanoparticles Containing a Combination of a Drug and an Antibody for the Treatment of Breast Cancer Brain Metastases.
Wyatt EA; Davis ME
Mol Pharm; 2020 Feb; 17(2):717-721. PubMed ID: 31916770
[TBL] [Abstract][Full Text] [Related]
16. Injectable hydrogels for the sustained delivery of a HER2-targeted antibody for preventing local relapse of HER2+ breast cancer after breast-conserving surgery.
Chen X; Wang M; Yang X; Wang Y; Yu L; Sun J; Ding J
Theranostics; 2019; 9(21):6080-6098. PubMed ID: 31534538
[TBL] [Abstract][Full Text] [Related]
17. Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by NEO100 in mouse models of brain-metastatic breast cancer.
Wang W; He H; Marín-Ramos NI; Zeng S; Swenson SD; Cho HY; Fu J; Beringer PM; Neman J; Chen L; Schönthal AH; Chen TC
Neuro Oncol; 2021 Oct; 23(10):1656-1667. PubMed ID: 33659980
[TBL] [Abstract][Full Text] [Related]
18. Viral transduction of the HER2-extracellular domain expands trastuzumab-based photoimmunotherapy for HER2-negative breast cancer cells.
Shimoyama K; Kagawa S; Ishida M; Watanabe S; Noma K; Takehara K; Tazawa H; Hashimoto Y; Tanabe S; Matsuoka J; Kobayashi H; Fujiwara T
Breast Cancer Res Treat; 2015 Feb; 149(3):597-605. PubMed ID: 25616354
[TBL] [Abstract][Full Text] [Related]
19. Pulsed-laser irradiation of multifunctional gold nanoshells to overcome trastuzumab resistance in HER2-overexpressing breast cancer.
Nunes T; Pons T; Hou X; Van Do K; Caron B; Rigal M; Di Benedetto M; Palpant B; Leboeuf C; Janin A; Bousquet G
J Exp Clin Cancer Res; 2019 Jul; 38(1):306. PubMed ID: 31299997
[TBL] [Abstract][Full Text] [Related]
20. Persistent expression of biologically active anti-HER2 antibody by AAVrh.10-mediated gene transfer.
Wang G; Qiu J; Wang R; Krause A; Boyer JL; Hackett NR; Crystal RG
Cancer Gene Ther; 2010 Aug; 17(8):559-70. PubMed ID: 20448672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
